Central Nervous System Effects of GLP-1 Receptor Agonists: A Systematic Review of Human Neuroimaging Studies.
GLP-1 drugs appear to work partly by calming reward-related brain activity, opening doors to treating addiction and other neurological conditions.
This NIH-led systematic review (37 studies) provides the most comprehensive synthesis to date of GLP-1RA CNS mechanisms in humans, showing consistent attenuation of reward-related brain activity across corticosubcortical circuits, with effects varying by metabolic status and attenuating over prolonged treatment. The findings provide mechanistic underpinning for GLP-1RA applications in addiction, psychiatric disorders, and neurodegeneration—rapidly expanding indications beyond obesity and diabetes.
What the study was
- Study design
- Systematic review (PubMed + Embase, inception to Jan 2026)
- Population
- Adults receiving GLP-1RAs across obesity, diabetes, psychiatric and neurodegenerative conditions
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Neuroscience & Biobehavioral Reviews
Why it surfaced
Systematic review from NIAAA/NIH authors; synthesizes 37 human neuroimaging studies on GLP-1RA CNS effects; growing clinical interest in GLP-1RAs for addiction and psychiatric indications; mechanistic insights directly relevant to informed prescribing and trial design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.